Concurrent chemoradiotherapy and salvage chemotherapy for advanced cervical cancer with a pedunculated cervical leiomyoma: a case report

Although concurrent chemoradiotherapy (CCRT) is an effective treatment for advanced cervical cancer, its use in advanced cervical cancer with a pedunculated cervical leiomyoma remains challenging. The prognosis of recurrent cervical cancer is poor, with a low possibility of complete response (CR). In this present study, after completion of external beam radiotherapy (EBRT) and chemotherapy (weekly cisplatin), we performed the resection of a pedunculated cervical leiomyoma. No malignant cells were identified in the pathological specimen. After the myoma resection, no cervical tumor was observed on follow-up magnetic resonance imaging (MRI). High-dose-rate intracavitary brachytherapy (HDR-ICBT) was also performed. Local control of the cervical tumor was achieved after 30 months of treatment. After CCRT, rectal hemorrhage was observed but was effectively controlled via local intervention. Twenty-four months after CCRT, the patient was given salvage chemotherapy (paclitaxel plus carboplatin) due to lymph node metastasis observed at the outside range of EBRT. Thirty months after CCRT, computed tomography showed that the metastatic lymph nodes had disappeared, and the patient achieved CR. Thus, for advanced cervical cancer with a pedunculated cervical leiomyoma, CCRT could be completed following myoma resection. In addition, salvage chemotherapy for lymph node metastasis might result in CR. In this present case, a gastrointestinal adverse event was observed after radiotherapy and salvage chemotherapy with paclitaxel plus carboplatin achieved CR.

Brachytherapy; Chemoradiotherapy; Combined modality therapy; Myoma; Uterine cervical neoplasm

[1] Buskwofie A, David-West G, Clare CA. A review of cervical cancer: incidence and disparities. Journal of the National Medical Association. 2020; 112: 229–232.

[2] Lewis TD, Malik M, Britten J, San Pablo AM, Catherino WH. A comprehensive review of the pharmacologic management of uterine leiomyoma. BioMed Research International. 2018; 2018: 2414609.

[3] Tiltman AJ. Leiomyomas of the uterine cervix. International Journal of Gynecological Pathology. 1998; 17: 231–234.

[4] Li X, Xia L, Chen X, Fu Y, Wu X. Simple conization and pelvic lymphadenectomy in early-stage cervical cancer: a retrospective analysis and review of the literature. Gynecologic Oncology. 2020; 158: 231–235.

[5] Matsuzaki S, Klar M, Mikami M, Shimada M, Grubbs BH, Fujiwara K, et al. Management of stage IIB cervical cancer: an overview of the current evidence. Current Oncology Reports. 2020; 22: 28.

[6] Marchetti C, Fagotti A, Tombolini V, Scambia G, De Felice F. Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: a systematic review and meta-analysis. Cancer Treatment Reviews. 2020; 83: 101945.

[7] Vinod SK, Caldwell K, Lau A, Fowler AR. A comparison of ICRU point doses and volumetric doses of organs at risk (OARs) in brachytherapy for cervical cancer. Journal of Medical Imaging and Radiation Oncology. 2011; 55: 304–310.

[8] Kumar L, Harish P, Malik PS, Khurana S. Chemotherapy and targeted therapy in the management of cervical cancer. Current Problems in Cancer. 2018; 42: 120–128.

[9] Takeshima N, Shimizu Y, Umezawa S, Hirai Y, Chen J, Fujimoto I, et al. Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma. Gynecologic Oncology. 1994; 54: 321–326.

[10] Borras G, Molina R, Xercavins J, Ballesta A, Iglesias J. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix. Gynecologic Oncology. 1995; 57: 205–211.

[11] Fujii S, Konishi I, Nanbu Y, Nonogaki H, Kobayashi F, Sagawa N, et al. Analysis of the levels of CA125, carcinoembryonic antigen, and CA19-9 in the cervical mucus for a detection of cervical adenocarcinoma. Cancer. 1988; 62: 541–547.

[12] Rim Nam H, Jae Huh S, Taik Park C, Kim B, Ahn G. A case of invasive squamous cell carcinoma on the surface of pedunculated cervical leiomyoma presenting an exophytic cervical cancer. Gynecologic Oncology. 2005; 97: 253–255.

[13] Zou W, Han Y, Zhang Y, Hu C, Feng Y, Zhang H, et al. Neoadjuvant chemotherapy plus surgery versus concurrent chemoradiotherapy in stage IB2-IIB cervical cancer: a systematic review and meta-analysis. PLoS One. 2019; 14: e0225264.

[14] Li H, Wu X, Cheng X. Advances in diagnosis and treatment of metastatic cervical cancer. Journal of Gynecologic Oncology. 2016; 27: e43.

[15] Toita T, Kakinohana Y, Ogawa K, Adachi G, Moromizato H, Nagai Y, et al. Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: analysis of dose and fractionation schedule. International Journal of Radiation Oncology, Biology, Physics. 2003; 56: 1344–1353.

[16] Song D, Kong W, Zhang T, Han C, Liu T, Jiao S, et al. A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer. Journal of Obstetrics and Gynaecology. 2019; 39: 389–394.

[17] Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017; 390: 1654–1663.